These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results
I'm LongbridgeAI, I can summarize articles.
Regeneron Pharmaceuticals Inc. reported strong Q4 earnings with adjusted earnings of $11.44 per share, surpassing expectations. Sales reached $3.88 billion, also above consensus. The company forecasts a GAAP gross margin of 79%-80% for fiscal 2026 and adjusted R&D expenses of $5.9-$6.1 billion. Following the earnings report, analysts revised their price targets: Truist lowered to $818, Cantor raised to $800, Wells Fargo to $800, and Morgan Stanley to $769. Regeneron shares rose 2.1% to $756.63.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments